Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 15, 2021

BioPharm International

  • BioPharm International-03-15-2021
  • Volume 2021 eBook
  • Issue 1

Resources, Guidelines, and Guidance Documents Directory

Find links to pertinent regulatory and standard setting resources, guidance documents, and guidelines.

Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.